UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-27598 IRIDEX CORPORATION (Exact name of Registrant as specified in its charter) Delaware 77-0210467 (State or other jurisdiction of in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-27598 IRIDEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 77-0210467 (State or other jurisdict ...

Financial Data and Key Metrics Changes - Total revenue for the second quarter of 2023 was $12.9 million, a decrease of approximately 7% compared to the same period last year, primarily due to declines in surgical and medical retina revenue and reduced royalty income from expired patents [6][48] - Gross profit for the second quarter was $5.4 million, down from $6.3 million in the prior year, with gross margin declining to 41.7% from 45.6% [22][48] - The net loss for the second quarter was $2.8 million, or $0.17 per share, compared to a net loss of $2.2 million, or $0.14 per share, for the same period in 2022 [50] Business Line Data and Key Metrics Changes - Revenue from the Cyclo G6 product family increased by 5% year-over-year to $3.7 million, with 15,500 probes sold, representing a 9% revenue growth on a 4% unit growth [21][37] - Retina product revenue declined to $6.9 million from $7.5 million in the prior year, attributed to macroeconomic uncertainties and a high interest rate environment [44][49] - Other revenue, including royalties and services, decreased by 15% to $2.3 million, primarily due to reduced royalty revenue from expired patents [49] Market Data and Key Metrics Changes - The company experienced lengthening sales cycles for capital equipment amid rising interest rates, although recent trends indicate stabilization in customer behavior [18][25] - The installed base of Cyclo G6 systems increased by 41 units in the quarter, with expectations for unit sales to range from 61,000 to 63,000 for the year [33][70] Company Strategy and Development Direction - The company aims to enhance its long-term growth through differentiated clinical value propositions in non-incisional glaucoma treatments and the launch of updated retina laser platforms [7][44] - Key initiatives include educating clinicians on updated dosing recommendations and targeting comprehensive ophthalmologists to increase adoption of glaucoma treatments [11][13] - The company is focused on preserving its cash runway while executing growth strategies, with plans to reduce operating expenses and inventory [20][36] Management's Comments on Operating Environment and Future Outlook - Management noted that the second half of the year may align more closely with expectations, as deferred orders from the previous quarter are expected to materialize [25] - The company is optimistic about the potential for growth in the glaucoma market, despite current mid-single-digit growth rates [34][80] - Management acknowledged the challenges in driving probe utilization but expressed confidence in the effectiveness of their educational initiatives and clinical evidence [27][88] Other Important Information - The company has adjusted its full-year revenue guidance to a range of $55 million to $57 million, down from a previous expectation of $57 million to $59 million [70] - The company is in the final stages of designing a large-scale multicenter prospective clinical trial to support the MicroPulse TLT treatment for moderate stage glaucoma patients [43] Q&A Session Summary Question: What is the outlook for the second half of the year? - Management indicated that orders deferred in the previous quarter are expected to come in, leading to a more positive outlook for the second half of the year [25] Question: How does the company plan to increase probe utilization? - The focus is on improving efficacy and safety through education and clinical evidence, which is essential for driving adoption among clinicians [27][88] Question: What are the expectations for the balance sheet and profitability? - Management emphasized ongoing efforts to reduce inventory and operating cash usage, with a focus on achieving profitability in the near future [79][80]

Education and Training • Expanding peer-reviewed publications • Seminars/webinar/wetlabs • KOL support • IRIDEX-sponsored clinical trials • Social media outreach Product Enhancements 6 • Commercial rollout of enhanced probe tip • Technique and protocol simplification focus 11 S a l e s C yc l e : F o c u s i n g o n E x i s t i n g + N e w C u s t o m e rs GLAUCOMA SPECIALIST PHYSICIAN EDUCATION Validation Conversion Commitment to Benefits Targeting HANDS-ON TRAINING 12 Key Takeaways Significant market oppo ...

IRIDEX Corporation (NASDAQ:IRIX) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group David Bruce - President and CEO Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants Scott Henry - ROTH Capital Tom Stephan - Stifel Operator Good day, and thank you for standing by. Welcome to the Fourth Quarter 2022 IRIDEX Conference Call. At this time, all participants are in a listen-only mode. After the speakers' present ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITY EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-27598 IRIDEX CORPORATION (Exact name of Registrant as specified in its charter) | Delaware | | | 77-0210467 | | --- | --- | --- | --- | | (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) | | | | | 1212 Terra Bella Avenu ...

IRIDEX Corporation (NASDAQ:IRIX) Q3 2022 Results Conference Call November 10, 2022 5:00 PM ET Company Participants David Bruce - Chief Executive Officer Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants Scott Henry - ROTH Capital Operator Good day, and thank you for standing by. Welcome to the IRIDEX Third Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-andanswer session [Operator Instr ...

IRIDEX Corporation (NASDAQ:IRIX) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Leigh Salvo - Investor Relations David Bruce - Chief Executive Officer Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants Tom Stephan - Stifel Scott Henry - ROTH Capital Operator Good day and thank you for standing by. Welcome to the IRIDEX Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentati ...

IRIDEX Corporation (NASDAQ:IRIX) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants David Bruce – Chief Executive Officer Hunter Cabi – Investor Relations Fuad Ahmad – Interim Chief Financial Officer Conference Call Participants Tom Stephan – Stifel Operator Hello. Thank you for standing by, and welcome to the IRIDEX First Quarter 2022 Earnings Conference Call. At this time all participants are in a listen-only mode. After the speaker presentation, there will be a question-andansw ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2021 was $15.3 million, up 24% from $12.3 million in Q4 2020, and total revenue for the full year increased 48% to $53.9 million from $36.4 million in 2020 [24][25] - Gross profit for Q4 was $6 million, an 8% increase from the same period last year, with a gross margin percentage of 39.3%, down from 45.4% in Q4 2020 [29] - Net loss for Q4 2021 was $2.4 million or $0.15 per share, compared to a loss of $0.01 per share for the same period in 2020 [31] Business Line Data and Key Metrics Changes - Cyclo G6 probe sales increased 13% year-over-year, with 15,200 units sold in Q4 2021 [25][12] - Retina product revenue improved significantly in Q4 to $9.1 million, a 31% increase compared to the prior year period, with PASCAL revenue contributing $1.6 million [26][27] - Total glaucoma product revenue for 2021 was $13.9 million, up 23% from 2020, while total retina revenue grew 72% year-over-year [26][27] Market Data and Key Metrics Changes - The company expects Cyclo G6 probe unit sales of 67,000 to 70,000 in 2022, representing approximately 18% growth at the midpoint [20] - The installed base of Cyclo G6 systems is expected to expand by 225 to 250 units in 2022 [21] - The company anticipates total revenue for 2022 to be between $57 million and $59 million [33] Company Strategy and Development Direction - The company aims to accelerate momentum gained in 2021 by supporting its global commercial team with increased clinical data and education programs [18] - Focus areas include expanding market penetration in the U.S. and internationally, particularly in China, and enhancing product development investments [19] - The company plans to leverage revenue growth to expand investments while maintaining a secure capital position [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating supply chain challenges and anticipates solid growth as capacity limits are lifted [22] - The company believes it can achieve growth rates of 20% to 30% as it matures various growth levers in the glaucoma market [41] - Management highlighted the opportunity to capture significant penetration into the moderate stage glaucoma patient population, estimating a potential for several hundred thousand procedures [44] Other Important Information - The company ended the year with cash and cash equivalents of $23.9 million, an increase of $12.2 million from the end of 2020, primarily due to the Topcon transaction [32] - Operating expenses for Q4 were $8.4 million, reflecting increased R&D spending and planned increases in sales and marketing activities [30] Q&A Session Summary Question: What are the important drivers for Cyclo G6 probe growth in 2022? - Management identified several growth areas, including moving clinicians to treat moderate-stage patients and increasing the number of users at existing sites [35][36] Question: What is the growth aspiration for the G6 business long-term? - Management believes the G6 business can achieve consistent growth of 20% or more as it penetrates the moderate-stage patient market [41] Question: Can you provide insights on the retina business for 2022? - Management indicated that while the retina market is relatively mature, they expect to gain market share and introduce new platforms later in the year [47][49] Question: What should be expected regarding gross margin for 2022? - Management anticipates gross margins in the mid-40s, with potential fluctuations based on revenue and product mix [51][52] Question: How is pricing expected to impact revenue in 2022? - Management noted that while there are pressures on costs, they expect to implement price increases to preserve margins, but competition will play a significant role [53][54]